Betta Pharmaceuticals Co., Ltd.
bettapharma.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
75
Active
14
Phase 3
10
Total enrollment
8,700
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ensartinib | — | — | — | 6 | |||
| Befotertinib + Icotinib placebo | — | — | — | — | — | 1 | |
| Icotinib + Befotertinib placebo | — | — | — | — | — | 1 | |
| MCLA-129 | — | — | — | — | — | 3 | |
| Befotertinib | — | — | — | — | — | 2 | |
| Icotinib | — | — | 27 | ||||
| BPI-572270 | — | — | — | — | — | 1 | |
| Pemetrexed + Carboplatin | — | — | — | — | — | 1 | |
| BPI-16350 | — | — | — | — | 3 | ||
| BPI-460372 | — | — | — | — | — | 1 | |
| Dose-Escalation (Phase Ia) CFT8919 | — | — | — | — | — | 1 | |
| Dose-Expansion (Phase Ib) CFT8919 | — | — | — | — | — | 1 | |
| Cohort-Expansion (Phase Ic) CFT8919 | — | — | — | — | — | 1 | |
| Rifampicin | — | — | — | — | — | 1 | |
| Itraconazole | — | — | — | — | — | 1 | |
| MCLA-129: 1500mg or 2000mg IV Q2W | — | — | — | — | — | 1 | |
| Befotertinib: 75 mg or 100 mg Po QD | — | — | — | — | — | 1 | |
| BPI-371153 | — | — | — | — | — | 1 |
Next readouts
- 2024-10
- 2024-12-31
- 2025-04-17
- 2025-06-01
- 2025-12
- 2025-12-09
- 2026-12
- 2028-04
- 2028-04-30
- 2028-04-30
Top conditions
- Non-small Cell Lung Cancer17
- Non-Small Cell Lung Cancer10
- NSCLC5
- Solid Tumor5
- Brain Metastases5
- EGFR Positive Non-small Cell Lung Cancer4
- Adenocarcinoma4
- Non-small-cell Lung Cancer3
Frequently asked questions about Betta Pharmaceuticals Co., Ltd.
- How many clinical trials does Betta Pharmaceuticals Co., Ltd. have on ClinicalTrials.gov?
- Betta Pharmaceuticals Co., Ltd. is listed as the lead sponsor on 75 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Betta Pharmaceuticals Co., Ltd.'s trials are in Phase 3?
- 10 of Betta Pharmaceuticals Co., Ltd.'s trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does Betta Pharmaceuticals Co., Ltd. focus on?
- Betta Pharmaceuticals Co., Ltd.'s most-studied conditions on ClinicalTrials.gov are Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer, NSCLC, Solid Tumor, Brain Metastases.
- When are Betta Pharmaceuticals Co., Ltd.'s next clinical trial readouts?
- Betta Pharmaceuticals Co., Ltd. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers”, expected around 2024-10.